Physician profile
Brent E Bunnell
NPI 1942344213
$13,943.22
in general payments reported to CMS, 2019-2025
46 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,971 · 2020: $2,171 · 2021: $1,907 · 2022: $2,206 · 2023: $2,089 · 2024: $2,041 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,688.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,838.23 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,341.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,250.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,087.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $973.40 | 2019-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $951.52 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $920.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $617.34 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $464.41 | 2019-2024 | Steglatro, Belsomra, Steglujan |
| Sanofi-Aventis U.S. LLC | $454.29 | 2019-2025 | |
| Astellas Pharma US INC | $438.05 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $397.40 | 2019-2025 | Otezla, Repatha, Evenity |
| Janssen Pharmaceuticals, INC | $394.12 | 2019-2024 | Spravato, Xarelto |
| Kowa Pharmaceuticals America, INC. | $319.02 | 2019-2023 | Seglentis, Livalo |
| Abbott Laboratories | $233.97 | 2021-2024 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Bunnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.